About arcturus therapeutics holdings inc - ARCT
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
ARCT At a Glance
Arcturus Therapeutics Holdings, Inc.
10628 Science Center Drive
San Diego, California 92121
| Phone | 1-858-900-2660 | Revenue | 67.22M | |
| Industry | Pharmaceuticals: Major | Net Income | -65,783,000.00 | |
| Sector | Health Technology | Employees | 111 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ARCT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.497 |
| Price to Book Ratio | 0.814 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.529 |
| Enterprise Value to Sales | -0.566 |
| Total Debt to Enterprise Value | -0.657 |
ARCT Efficiency
| Revenue/Employee | 605,594.595 |
| Income Per Employee | -592,639.64 |
| Receivables Turnover | 12.081 |
| Total Asset Turnover | 0.219 |
ARCT Liquidity
| Current Ratio | 6.637 |
| Quick Ratio | 6.637 |
| Cash Ratio | 6.347 |
ARCT Profitability
| Gross Margin | 95.50 |
| Operating Margin | -111.505 |
| Pretax Margin | -97.861 |
| Net Margin | -97.861 |
| Return on Assets | -21.385 |
| Return on Equity | -28.918 |
| Return on Total Capital | -27.526 |
| Return on Invested Capital | -26.274 |
ARCT Capital Structure
| Total Debt to Total Equity | 11.682 |
| Total Debt to Total Capital | 10.46 |
| Total Debt to Total Assets | 9.219 |
| Long-Term Debt to Equity | 9.713 |
| Long-Term Debt to Total Capital | 8.697 |